Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Arrizabalaga

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Sangre|January 1, 1979
[Prophylactic treatment in hemophilia. Resume of the results of a multicentric program]B Cuesta, B Arrizabalaga, M Hernández, et al.
Hemoglobin|March 11, 1998
A case of Hb J-Chicago [beta 76(E20)Ala-->Asp] in a Spanish familyB Arrizabalaga, A Erkiaga, A Villegas, et al.
Revista De Medicina De La Universidad De Navarra|September 1, 1982
[Cutaneous infiltration in multiple myeloma]B Cuesta, B Arrizabalaga, J Fernández Díaz, et al.
Sangre|January 1, 1980
[Coagulation and fibrinolysis alterations in renal failure (author's transl)]E Rocha, A Sánchez Ibarrola, B Arrizabalaga, et al.
Sangre|January 1, 1981
[Application if different techniques to the diagnosis of von Willebrand's disease (author's transl)]J M Solana, E Rocha, B Arrizabalaga, et al.
Blood|September 25, 1998
Rh-deficiency of the regulator type caused by splicing mutations in the human RH50 geneB Chérif-Zahar, G Matassi, V Raynal, et al.
Revista De Medicina De La Universidad De Navarra|December 1, 1980
[Hormonal contraceptive therapy and thromboembolic disease]M J Narvaiza, M Hernández, B Arrizabalaga, et al.
American Journal of Hematology|November 14, 2000
Hb Johnstown [beta 109 (G11) Val-->Leu]: second case described and associated for the first time with beta(0)-thalassemia in two Spanish familiesP Ropero, A Villegas, A F González, et al.
Sangre|June 1, 1997
[Identification of 5 variants of the hemoglobin beta chain using DNA analysis (amplification, sequencing and restriction enzymes)]E Martí, P Ropero, F Ataulfo González, et al.
Current Medical Research and Opinion|March 9, 2011
Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of responseA Villegas, B Arrizabalaga, C Fernández-Lago, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Sangre|January 1, 1979
[Prophylactic treatment in hemophilia. Resume of the results of a multicentric program]B Cuesta, B Arrizabalaga, M Hernández, et al.
Hemoglobin|March 11, 1998
A case of Hb J-Chicago [beta 76(E20)Ala-->Asp] in a Spanish familyB Arrizabalaga, A Erkiaga, A Villegas, et al.
Revista De Medicina De La Universidad De Navarra|September 1, 1982
[Cutaneous infiltration in multiple myeloma]B Cuesta, B Arrizabalaga, J Fernández Díaz, et al.
Sangre|January 1, 1980
[Coagulation and fibrinolysis alterations in renal failure (author's transl)]E Rocha, A Sánchez Ibarrola, B Arrizabalaga, et al.
Sangre|January 1, 1981
[Application if different techniques to the diagnosis of von Willebrand's disease (author's transl)]J M Solana, E Rocha, B Arrizabalaga, et al.
Blood|September 25, 1998
Rh-deficiency of the regulator type caused by splicing mutations in the human RH50 geneB Chérif-Zahar, G Matassi, V Raynal, et al.
Revista De Medicina De La Universidad De Navarra|December 1, 1980
[Hormonal contraceptive therapy and thromboembolic disease]M J Narvaiza, M Hernández, B Arrizabalaga, et al.
American Journal of Hematology|November 14, 2000
Hb Johnstown [beta 109 (G11) Val-->Leu]: second case described and associated for the first time with beta(0)-thalassemia in two Spanish familiesP Ropero, A Villegas, A F González, et al.
Sangre|June 1, 1997
[Identification of 5 variants of the hemoglobin beta chain using DNA analysis (amplification, sequencing and restriction enzymes)]E Martí, P Ropero, F Ataulfo González, et al.
Current Medical Research and Opinion|March 9, 2011
Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of responseA Villegas, B Arrizabalaga, C Fernández-Lago, et al.
Pageof 2